Prebiopsy multiparametric magnetic resonance imaging plus targeted biopsy is associated with increased detection of clinically significant prostate cancer versus ultrasonography-guided systematic biopsy alone, study data show.
68Ga-prostate-specific membrane antigen-11 should be the “tracer of choice” for PET–CT to detect the postoperative biochemical recurrence of prostate cancer, say researchers who conducted a comparative imaging trial.
Older individuals with HIV and prostate cancer have worse outcomes than corresponding cancer patients without HIV, according to a large database study from the USA.
Current decision aids probably have no influence on whether physicians and patients discuss prostate cancer screening or decide to undergo screening, according to a systematic review and meta-analysis.
Older prostate cancer patients who use androgen deprivation therapy may be at increased risk for developing Alzheimer’s disease or dementia, findings indicate.
Rates of active surveillance or watchful waiting among younger men with low‐risk prostate cancer have quadrupled in recent years but remain below those for older men, despite no apparent increased mortality risk, research shows.
Combining abiraterone acetate with a relatively high dose of prednisone or dexamethasone may reduce mineralocorticoid excess toxic effects, but can result in increased metabolic toxicity, study data show.
Among the potential active treatment options for prostate cancer, external‐beam radiotherapy alone results in the best preservation of sexual function up to 2 years after treatment, population-based study data show.
Following treatment with the autologous cellular immunotherapy sipuleucel-T for metastatic castration-resistant prostate cancer, African–American men can expect to live longer than their Caucasian counterparts, indicates an analysis of the PROCEED registry.
Men with metastatic castration-sensitive prostate cancer derive a significant overall survival benefit from the addition of enzalutamide to standard testosterone suppression, show phase III trial results.
The outcomes of nondiabetic men with metastatic castration-resistant prostate cancer are not improved with the addition of metformin to docetaxel, finds the French TAXOMET trial.
The degree of response to olaparib among patients with heavily pretreated metastatic castration-resistant prostate cancer varies according to the type of DNA damage repair alteration the tumor carries, research shows.
Supplementing androgen deprivation therapy with apalutamide leads to significant improvements in survival outcomes in men with metastatic castration-sensitive prostate cancer, show phase III trial results.
Men with nonmetastatic castration-resistant prostate cancer enrolled in the ARAMIS trial report favorable quality of life outcomes with darolutamide relative to placebo.
Research published in JAMA Oncology confirms that prostate cancer-specific mortality is not significantly different between Black and White men with nonmetastatic disease when access to care and treatment is comparable.
In men with prostate cancer and diabetes, higher glycated hemoglobin levels are associated with an increased risk for developing metastases and castration-resistant disease, findings indicate.
Use of 5α-reductase inhibitors, typically for benign prostatic hyperplasia, may delay prostate cancer diagnosis and thus increase mortality risk, show results of a large population-based cohort study.
A single dose of high-dose rate brachytherapy prevents biochemical recurrence for at least 3 years in patients with low-risk prostate cancer, but is less effective among those with higher-risk disease, researchers report.